
  
    
      
        Introduction_NNP
        A_DT characteristic_JJ feature_NN of_IN many_JJ cancer_NN types_NNS is_VBZ their_PRP$
        ability_NN to_TO metastasise_NN to_TO the_DT skeleton_NN ._. At_IN the_DT skeletal_NN
        site_NN of_IN metastatic_JJ invasion_NN ,_, the_DT bone_NN metabolism_NN is_VBZ
        dysregulated_JJ and_CC bone_NN resorption_NN or_CC bone_NN formation_NN ,_, or_CC
        both_DT ,_, is_VBZ upregulated_JJ ._. Bone_NNP is_VBZ the_DT most_RBS common_JJ target_NN site_NN
        of_IN metastatic_JJ invasion_NN in_IN breast_NN cancer_NN [_NN 1_CD ]_NN ._. This_DT is_VBZ of_IN
        clinical_JJ importance_NN as_IN metastatic_JJ bone_NN disease_NN is_VBZ
        associated_VBN with_IN increased_VBN morbidity_NN and_CC excess_JJ mortality_NN [_NN
        2_CD ]_NN ._. To_TO initiate_VB successful_JJ preventive_JJ therapy_NN it_PRP is_VBZ thus_RB
        imperative_JJ that_IN the_DT bone_NN metastases_NNS are_VBP detected_VBN early_JJ [_NN 3_CD
        ]_NN ._.
        The_DT diagnosis_NN of_IN bone_NN metastases_NNS is_VBZ usually_RB performed_VBN
        through_IN bone_NN scintigraphy_NN ._. However_RB ,_, this_DT technique_NN is_VBZ
        invasive_JJ and_CC is_VBZ not_RB sensitive_JJ enough_RB for_IN detection_NN of_IN the_DT
        very_RB early_JJ stages_NNS of_IN metastasis_NNS [_NN 4_CD ]_NN ._. Biochemical_NNP markers_NNS
        of_IN bone_NN turnover_NN are_VBP noninvasive_JJ and_CC may_MD potentially_RB
        provide_VB a_DT more_RBR sensitive_JJ measure_NN of_IN metastatic_JJ skeletal_NN
        invasion_NN ,_, but_CC clinical_JJ applications_NNS of_IN the_DT bone_NN turnover_NN
        markers_NNS have_VBP not_RB been_VBN thoroughly_RB evaluated_VBN for_IN such_JJ a_DT
        clinical_JJ role_NN ._.
        Degradation_NNP products_NNS derived_VBN from_IN the_DT α_NN 1_CD chain_NN of_IN type_NN
        I_PRP collagen_NN (_( CTX_NNP )_) have_VBP been_VBN shown_VBN to_TO provide_VB a_DT sensitive_JJ and_CC
        specific_JJ index_NN of_IN bone_NN resorption_NN [_NN 5_CD 6_CD ]_NN ._. Preliminary_JJ
        studies_NNS have_VBP suggested_VBN that_IN the_DT CTX_NNP marker_NN may_MD be_VB
        applicable_JJ for_IN monitoring_VBG skeletal_NN metastases_NNS in_IN breast_NN and_CC
        prostate_NN cancer_NN patients_NNS [_NN 7_CD 8_CD ]_NN ._. The_DT epitope_NN recognised_JJ
        in_IN the_DT CTX_NNP assays_NNS comprises_VBZ the_DT six_CD residues_NNS AHDGGR_NNP
        1209_CD -_: 1214_CD of_IN the_DT collagen_NN type_NN I_PRP C-_NNP terminal_NN telopeptide_NN ._. The_DT
        aspartyl-glycine_JJ site_NN (_( DG_NNP )_) within_IN this_DT epitope_NN is_VBZ
        susceptible_JJ to_TO spontaneous_JJ nonenzymatic_JJ rearrangement_NN ,_, as_IN
        outlined_VBN in_IN Fig_NNP ._. 1_LS ._.
        CTX_NNP fragments_NNS derived_VBN from_IN newly_RB synthesised_JJ collagen_NN
        are_VBP of_IN the_DT native_JJ peptide_NN form_NN (_( L-_NNP aspartyl_NN peptide_NN [_NN α_NN L_NNP ]_NN )_) ,_,
        where_WRB the_DT aspartic_JJ acid_NN residue_NN (_( D_NNP 1211_CD )_) is_VBZ on_IN the_DT
        L-_NNP enantiomeric_JJ form_NN and_CC is_VBZ linked_VBN to_TO the_DT glycine_NN residue_NN (_( G_NNP
        1212_CD )_) through_IN a_DT peptide_NN bond_NN ._. Collagen_NNP and_CC CTX_NNP fragments_NNS
        will_MD rearrange_VB with_IN age_NN to_TO three_CD age-modified_JJ forms_NNS :_: the_DT
        isomerised_JJ form_NN (_( L-_NNP isoaspartyl_NN peptide_NN [_NN β_NN L_NNP ]_NN )_) ,_, where_WRB the_DT
        bond_NN between_IN the_DT aspartic_JJ acid_NN and_CC glycine_NN residue_NN goes_VBZ
        through_IN the_DT β-carboxyl_JJ group_NN of_IN the_DT aspartyl_NN residue_NN ;_: the_DT
        racemised_JJ form_NN (_( D-_NNP aspartyl_NN peptide_NN [_NN α_NN D_NNP ]_NN )_) ,_, where_WRB the_DT
        aspartic_JJ acid_NN (_( D_NNP 1211_CD )_) is_VBZ on_IN a_DT D-_NNP enantiomeric_JJ form_NN ;_: and_CC the_DT
        isomerised_JJ and_CC racemised_JJ form_NN (_( D-_NNP isoaspartyl_NN peptide_NN [_NN β_NN
        D_NNP ]_NN )_) [_NN 9_CD ]_NN ._. The_DT relative_JJ accumulation_NN of_IN the_DT three_CD
        age-modified_JJ forms_NNS is_VBZ dependent_JJ on_IN the_DT balance_NN between_IN
        anabolic_JJ and_CC catabolic_JJ processes_NNS in_IN bone_NN ,_, and_CC pathologic_JJ
        situations_NNS affecting_VBG these_DT processes_VBZ may_MD thus_RB also_RB affect_VB
        the_DT relative_JJ amounts_NNS of_IN the_DT four_CD CTX_NNP forms_NNS [_NN 9_CD 10_CD 11_CD ]_NN
        ._.
        It_PRP has_VBZ been_VBN shown_VBN that_IN in_IN Paget_NNP 's_POS disease_NN of_IN bone_NN ,_, a_DT
        condition_NN characterised_JJ by_IN a_DT localised_JJ upregulation_NN of_IN bone_NN
        turnover_NN ,_, there_EX is_VBZ a_DT significant_JJ increase_NN in_IN the_DT ratio_NN
        between_IN the_DT native_JJ peptide_NN form_NN of_IN CTX_NNP (_( α_NN L_NNP )_) and_CC the_DT
        age-modified_JJ forms_NNS (_( β_NN L_NNP ,_, D-_NNP isoaspartyl_NN peptide_NN and_CC α_NN D_NNP )_) [_NN 9_CD
        ]_NN ._. The_DT use_NN of_IN CTX_NNP ratios_NNS may_MD thus_RB be_VB indicative_JJ of_IN the_DT
        significant_JJ decrease_NN in_IN the_DT residence_NN time_NN and_CC therefore_RB
        the_DT average_JJ age_NN of_IN the_DT resorbed_JJ bone_NN collagen_NN type_NN I_PRP
        fragments_VBZ in_IN Pagetic_NNP patients_NNS [_NN 9_CD ]_NN ._. This_DT indicates_VBZ that_IN
        perturbations_NNS in_IN the_DT normally_RB well-regulated_JJ process_NN of_IN
        bone_NN turnover_NN can_MD result_VB in_IN changes_NNS in_IN the_DT half-life_NN of_IN
        collagen_NN type_NN I_PRP within_IN the_DT bone_NN matrix_NN ._. This_DT in_IN turn_NN will_MD
        result_VB in_IN increased_VBN amounts_NNS of_IN the_DT newly_RB synthesised_JJ α_NN LCTX_NNP
        form_NN in_IN the_DT circulating_VBG pool_NN of_IN CTX_NNP fragments_NNS that_WDT is_VBZ
        reflected_VBN in_IN the_DT elevated_VBD ratios_NNS [_NN 9_CD 10_CD 11_CD ]_NN ._.
        Metastatic_NNP bone_NN cancer_NN will_MD also_RB affect_VB the_DT balance_NN
        between_IN the_DT anabolic_JJ and_CC catabolic_JJ processes_NNS at_IN the_DT local_JJ
        site_NN of_IN invasion_NN ._. The_DT measurement_NN of_IN CTX_NNP isoforms_NNS ,_, and_CC the_DT
        ratios_NNS between_IN the_DT native_JJ α_NN Lform_NNP and_CC the_DT age-modified_JJ
        forms_NNS of_IN CTX_NNP ,_, indicative_JJ of_IN the_DT age_NN of_IN the_DT resorbed_JJ
        collagen_NN fragments_NNS ,_, may_MD thus_RB provide_VB clinical_JJ useful_JJ
        information_NN for_IN diagnosing_VBG and_CC monitoring_VBG bone_NN metastasis_NNS
        occurrence_NN in_IN cancer_NN patients_NNS [_NN 11_CD ]_NN ._. Such_JJ an_DT application_NN
        of_IN the_DT CTX_NNP bone_NN resorption_NN markers_NNS may_MD be_VB especially_RB
        relevant_JJ for_IN breast_NN cancer_NN patients_NNS ,_, who_WP have_VBP a_DT high_JJ risk_NN
        of_IN developing_VBG bone_NN metastases_NNS ._.
        In_IN the_DT present_JJ study_NN ,_, our_PRP$ aim_NN was_VBD to_TO assess_VB the_DT clinical_JJ
        utility_NN of_IN the_DT different_JJ CTX_NNP isoforms_NNS ,_, as_RB well_RB as_IN the_DT
        ratios_NNS between_IN the_DT isoforms_NNS ,_, to_TO detect_VB breast_NN
        cancer-induced_JJ bone_NN metastases_NNS ._. For_IN this_DT purpose_NN ,_, the_DT
        urinary_JJ CTX_NNP isoforms_NNS α_NN L_NNP ,_, β_NN L_NNP ,_, and_CC α_NN Dwere_NNP quantified_VBN by_IN
        immunoassay_NN in_IN healthy_JJ premenopausal_NN and_CC postmenopausal_NN
        women_NNS ,_, and_CC in_IN women_NNS affected_VBN with_IN breast_NN cancer_NN either_CC with_IN
        or_CC without_IN bone_NN metastases_NNS ._.
      
      
        Patients_NNS and_CC methods_NNS
        
          Study_NN population_NN
          Urine_NNP samples_NNS were_VBD collected_VBN as_IN the_DT morning_NN void_NN from_IN
          24_CD healthy_JJ premenopausal_NN women_NNS (_( age_NN [_NN mean_NN ±_NN standard_JJ
          deviation_NN (_( SD_NNP )_) ]_NN ,_, 33_CD ._. 9_CD ±_NN 5_CD ._. 6_CD years_NNS )_) and_CC 31_CD healthy_JJ
          postmenopausal_NN women_NNS (_( age_NN 55_CD ._. 1_LS ±_NN 2_CD ._. 7_CD years_NNS )_) ._. In_IN addition_NN ,_,
          123_CD female_JJ patients_NNS with_IN histologically_RB confirmed_VBD breast_NN
          cancer_NN participated_VBD in_IN the_DT study_NN ._. Eight_CD patients_NNS were_VBD
          hypercalcemic_JJ (_( serum_NN calcium_NN >_NN 2_CD ._. 7_CD mmol_NN /_NN l_NN ,_, albumin_NN
          corrected_VBN )_) ,_, had_VBD radiologically_RB confirmed_VBN bone_NN metastases_NNS
          and_CC were_VBD 54_CD ._. 4_LS ±_NN 12_CD ._. 0_CD years_NNS of_IN age_NN (_( HC_NNP +_NN patients_NNS )_) ._. One_CD
          hundred_CD patients_NNS were_VBD normocalcemic_JJ (_( serum_NN calcium_NN
          between_IN 2_CD ._. 0_CD and_CC 2_CD ._. 7_CD mmol_NN /_NN l_NN ,_, albumin_NN corrected_VBN )_) ,_, had_VBD
          radiologically_RB confirmed_VBN bone_NN metastases_NNS and_CC were_VBD 54_CD ._. 4_LS ±_NN
          12_CD ._. 0_CD years_NNS of_IN age_NN (_( NC_NNP +_NN patients_NNS )_) ._. Finally_RB ,_, 15_CD breast_NN
          cancer_NN patients_NNS (_( 54_CD ._. 5_LS ±_NN 12_CD ._. 3_LS years_NNS of_IN age_NN )_) were_VBD
          normocalcemic_JJ ,_, had_VBD early_JJ stage_NN (_( nonmetastatic_JJ )_) cancer_NN but_CC
          were_VBD without_IN radiological_JJ signs_NNS of_IN bone_NN metastases_NNS
          (_( NC-patients_NNP )_) ._.
          Fifty_NNP per_IN cent_NN ,_, 49_CD %_NN and_CC 53_CD %_NN of_IN subjects_NNS were_VBD
          premenopausal_NN in_IN the_DT HC_NNP +_NN ,_, NC_NNP +_NN and_CC NC-_NNP patient_NN groups_NNS ,_,
          respectively_RB ._. There_EX was_VBD no_DT statistical_JJ difference_NN between_IN
          the_DT proportions_NNS of_IN premenopausal_NN women_NNS in_IN the_DT three_CD
          groups_NNS ._.
          The_DT presence_NN or_CC absence_NN of_IN bone_NN metastasis_NNS in_IN patients_NNS
          was_VBD determined_VBN by_IN bone_NN scintigraphy_NN ,_, and_CC was_VBD confirmed_VBN by_IN
          conventional_JJ radiography_NN (_( X-_NNP ray_NN )_) as_IN necessary_JJ ._. All_DT study_NN
          subjects_NNS had_VBD serum_NN creatinine_NN <_NN 265_CD μmol_NN /_NN l_NN ,_, and_CC
          received_VBD endocrine_NN therapy_NN and_CC /_NN or_CC an_DT
          anthracycline-containing_JJ regimen_NN ._. Some_DT patients_NNS had_VBD
          additional_JJ radiotherapy_NN in_IN the_DT event_NN of_IN clinical_JJ symptoms_NNS
          (_( e_SYM ._. g_SYM ._. bone_NN pain_NN ,_, instability_NN )_) ._. The_DT use_NN of_IN antineoplastic_JJ
          hormonal_NN treatment_NN (_( 20_CD mg_NN tamoxifen_NN ,_, 500_CD mg_NN
          aminoglutethimide_NN ,_, 500_CD mg_NN provera_NN )_) was_VBD allowed_VBN ,_, but_CC none_NN
          of_IN the_DT patients_NNS were_VBD receiving_VBG bisphosphonate_NN therapy_NN
          prior_RB to_TO entry_NN into_IN the_DT study_NN ._. Informed_NNP ,_, written_VBN consent_NN
          was_VBD obtained_VBN from_IN all_DT participants_NNS according_VBG to_TO the_DT
          Helsinki_NNP Declaration_NNP of_IN 1975_CD ,_, as_IN revised_VBN in_IN 1983_CD ._. The_DT
          study_NN was_VBD approved_VBN by_IN the_DT local_JJ human_JJ investigations_NNS
          committee_NN ._.
        
        
          Measurement_NNP of_IN CTX_NNP isoforms_NNS by_IN immunoassay_NN
          analysis_NN
          The_DT α-_NN CrossLaps_NNP radioimmunoassay_NN [_NN 12_CD ]_NN and_CC the_DT
          Cross-_NNP Laps_NNP ELISA_NNP [_NN 13_CD ]_NN are_VBP commercially_RB available_JJ
          immunoassays_NNS specific_JJ for_IN the_DT native_JJ (_( α_NN L_NNP )_) and_CC isomerised_JJ
          (_( β_NN L_NNP )_) forms_NNS of_IN CTX_NNP ,_, respectively_RB ._. The_DT assays_NNS were_VBD
          performed_VBN as_IN recommended_VBN by_IN the_DT manufacturer_NN (_( Nordic_NNP
          Bioscience_NNP Diagnostics_NNPS ,_, Herlev_NNP ,_, Denmark_NNP )_) ._.
          The_DT α_NN D-CTX_NNP ELISA_NNP is_VBZ a_DT competitive_JJ assay_NN based_VBN on_IN
          polyclonal_NN rabbit_NN antibodies_NNS for_IN the_DT α_NN Dform_NNP of_IN CTX_NNP ._. The_DT
          assay_NN has_VBZ been_VBN described_VBN elsewhere_RB [_NN 9_CD ]_NN ._. All_DT
          determinations_NNS of_IN urinary_JJ CTX_NNP were_VBD corrected_VBN for_IN
          creatinine_NN ._. The_DT three_CD CTX_NNP assays_NNS were_VBD calibrated_VBN using_VBG
          synthetic_JJ CTX_NNP standards_NNS ,_, the_DT concentration_NN of_IN which_WDT had_VBD
          been_VBN determined_VBN by_IN analysis_NN of_IN the_DT total_JJ amino_JJ acid_NN
          composition_NN as_IN described_VBN previously_RB [_NN 14_CD ]_NN ._.
        
        
          Statistical_NNP analysis_NN
          Biochemical_NNP data_NNS were_VBD compared_VBN between_IN groups_NNS using_VBG
          the_DT Mann-_NNP Whitney_NNP U_NNP test_NN (_( two-tailed_JJ )_) ._. For_IN all_DT tests_NNS 
          P_NN ≤_NN 0_CD ._. 05_CD was_VBD considered_VBN
          significant_JJ ._. The_DT discriminatory_JJ power_NN of_IN the_DT different_JJ
          CTX_NNP isoforms_NNS or_CC CTX_NNP ratios_NNS in_IN distinguishing_VBG groups_NNS from_IN
          controls_NNS was_VBD assessed_VBN using_VBG 
          T_NN or_CC 
          Z_NNP scores_NNS (_( i_NNP ._. e_SYM ._. number_NN of_IN SDs_NNP from_IN
          the_DT mean_NN of_IN the_DT controls_NNS )_) ._.
        
      
      
        Results_NNS
        The_DT urinary_JJ excretion_NN of_IN all_DT CTX_NNP forms_NNS was_VBD significantly_RB
        higher_JJR (_( 
        P_NN <_NN 0_CD ._. 001_CD )_) in_IN the_DT postmenopausal_NN
        group_NN when_WRB compared_VBN with_IN the_DT premenopausal_NN women_NNS ,_, with_IN
        approximately_RB 2_CD ._. 5_CD -_: fold_VB higher_JJR levels_NNS (_( Table_NNP 1_LS )_) ._. When_WRB ratios_NNS
        between_IN the_DT newly_RB synthesised_JJ α_NN Lform_NNP and_CC the_DT age-modified_JJ
        forms_NNS (_( β_NN Land_NNP α_NN D_NNP )_) were_VBD calculated_VBN ,_, only_RB minor_NN and_CC
        nonsignificant_NN differences_NNS were_VBD observed_VBN between_IN
        premenopausal_NN and_CC postmenopausal_NN women_NNS ._. In_IN patients_NNS with_IN
        breast_NN cancer-induced_JJ bone_NN metastases_NNS ,_, the_DT urinary_JJ
        excretion_NN of_IN the_DT newly_RB synthesised_JJ α_NN LCTX_NNP form_NN was_VBD more_RBR
        increased_JJ than_IN the_DT age-modified_JJ forms_NNS β_NN Land_NNP α_NN D_NNP ._. Compared_VBN
        with_IN NC-_NNP patients_NNS ,_, the_DT HC_NNP +_NN patients_NNS had_VBD a_DT 3_CD ._. 4_CD -_: fold_VB
        elevation_NN in_IN α_NN LCTX_NNP and_CC the_DT NC_NNP +_NN patients_NNS had_VBD 2_CD ._. 2_CD -_: fold_VB
        higher_JJR levels_NNS of_IN α_NN LCTX_NNP (_( 
        P_NN <_NN 0_CD ._. 01_CD )_) ._. The_DT levels_NNS of_IN α_NN DCTX_NNP ,_,
        representing_VBG the_DT oldest_JJS form_NN of_IN CTX_NNP ,_, were_VBD increased_VBD
        2_CD ._. 4_CD -_: fold_VB and_CC 1_CD ._. 7_CD -_: fold_VB in_IN HC_NNP +_NN patients_NNS and_CC in_IN NC_NNP +_NN patients_NNS
        compared_VBN with_IN NC-_NNP patients_NNS (_( Fig_NNP ._. 2_LS )_) ._. The_DT ratio_NN between_IN the_DT
        nonisomerised_JJ α_NN Lform_NNP and_CC the_DT racemised_JJ α_NN Dform_NNP of_IN CTX_NNP was_VBD
        consequently_RB increased_VBN in_IN NC_NNP +_NN patients_NNS and_CC in_IN HC_NNP +_NN patients_NNS
        2_CD ._. 2_CD and_CC 1_CD ._. 5_CD times_NNS ,_, respectively_RB ,_, when_WRB compared_VBN with_IN NC-_NNP
        patients_NNS ,_, and_CC increased_VBD 2_CD ._. 4_CD and_CC 1_CD ._. 6_CD times_NNS ,_, respectively_RB ,_,
        compared_VBN with_IN postmenopausal_NN patients_NNS ._. However_RB ,_, these_DT
        increases_NNS in_IN the_DT α_NN L_NNP /_NN α_NN Dratio_NNP did_VBD not_RB reach_VB statistical_JJ
        significance_NN as_IN evaluated_VBN by_IN nonparametric_JJ statistics_NNS ._.
        The_DT ability_NN of_IN the_DT various_JJ CTX_NNP forms_NNS and_CC CTX_NNP ratios_NNS to_TO
        discriminate_JJ between_IN patients_NNS with_IN bone_NN metastases_NNS (_( HC_NNP +_NN
        patients_NNS and_CC NC_NNP +_NN patients_NNS )_) and_CC patients_NNS without_IN bone_NN
        metastases_NNS (_( NC-_NNP patients_NNS )_) was_VBD assessed_VBN by_IN 
        Z_NNP -_: score_NN analysis_NN using_VBG the_DT mean_NN and_CC
        SD_NNP of_IN the_DT NC-_NNP patient_NN group_NN (_( Fig_NNP ._. 3_LS )_) ._. This_DT analysis_NN
        revealed_VBD that_IN the_DT α_NN LCTX_NNP levels_NNS provided_VBD the_DT best_JJS
        differentiation_NN between_IN patients_NNS with_IN metastases_NNS (_( HC_NNP +_NN
        patients_NNS and_CC NC_NNP +_NN patients_NNS )_) and_CC nonmetastasised_JJ controls_NNS
        (_( Fig_NNP ._. 3_LS )_) ._.
        Although_IN the_DT α_NN L_NNP /_NN α_NN Dratio_NNP displayed_VBD the_DT highest_JJS mean_NN 
        Z_NNP score_NN ,_, the_DT urinary_JJ excretion_NN of_IN the_DT
        α_NN LCTX_NNP form_NN still_RB appeared_VBD to_TO have_VB the_DT best_JJS ability_NN to_TO
        identify_VB patients_NNS affected_VBN by_IN bone_NN metastases_NNS ._. Thus_RB ,_, 58_CD %_NN of_IN
        patients_NNS affected_VBN by_IN bone_NN metastases_NNS had_VBD significantly_RB
        increased_VBN α_NN LCTX_NNP values_NNS (_( 
        Z_NNP score_NN >_NN 2_LS )_) compared_VBN with_IN breast_NN
        cancer_NN patients_NNS without_IN bone_NN metastases_NNS (_( NC-_NNP patients_NNS )_)
        (_( Fig_NNP ._. 3_LS )_) ._. In_IN comparison_NN ,_, 30_CD %_NN of_IN patients_NNS affected_VBN by_IN bone_NN
        metastases_NNS had_VBD α_NN L_NNP /_NN α_NN Dratios_NNP more_JJR than_IN 2_CD SDs_NNP above_IN the_DT
        normal_JJ postmenopausal_NN mean_NN (_( Fig_NNP ._. 3_LS )_) ._. In_IN addition_NN ,_, whereas_IN
        only_RB 27_CD %_NN of_IN patients_NNS affected_VBN by_IN bone_NN metastases_NNS had_VBD α_NN LCTX_NNP
        values_NNS below_IN the_DT mean_NN of_IN nonmetastasised_JJ controls_NNS
        (_( NC-patients_NNP )_) ,_, 52_CD %_NN of_IN these_DT patients_NNS had_VBD α_NN L_NNP /_NN α_NN Dratios_NNP
        below_IN this_DT value_NN (_( Fig_NNP ._. 3_LS )_) ._.
      
      
        Discussion_NNP
        In_IN the_DT present_JJ study_NN ,_, the_DT clinical_JJ utility_NN of_IN assays_NNS for_IN
        the_DT various_JJ CTX_NNP forms_NNS in_IN the_DT assessment_NN of_IN breast_NN
        cancer-induced_JJ bone_NN metastases_NNS was_VBD investigated_VBN ._.
        The_DT urinary_JJ concentration_NN of_IN all_DT four_CD CTX_NNP isoforms_NNS was_VBD
        initially_RB measured_VBN in_IN reference_NN populations_NNS of_IN healthy_JJ
        premenopausal_NN and_CC postmenopausal_NN women_NNS ._. The_DT levels_NNS of_IN the_DT
        three_CD CTX_NNP isoforms_NNS α_NN L_NNP ,_, β_NN Land_NNP α_NN Dwere_NNP 2_CD ._. 3_CD -_: fold_VB to_TO 2_CD ._. 7_CD -_: fold_VB
        higher_JJR in_IN the_DT postmenopausal_NN women_NNS (_( Table_NNP 1_LS )_) ,_, in_IN accordance_NN
        with_IN previous_JJ reports_NNS of_IN CTX_NNP levels_NNS during_IN the_DT menopause_NN [_NN
        15_CD ]_NN ._. As_IN all_DT forms_NNS were_VBD elevated_VBD to_TO the_DT same_JJ magnitude_NN in_IN
        postmenopause_NN ,_, the_DT ratios_NNS between_IN the_DT newly_RB synthesised_JJ α_NN
        LCTX_NNP form_NN and_CC the_DT older_JJR β_NN Land_NNP α_NN DCTX_NNP forms_NNS was_VBD not_RB
        significantly_RB different_JJ in_IN premenopausal_NN and_CC postmenopausal_NN
        women_NNS ._. This_DT indicates_VBZ that_IN the_DT average_JJ '_POS age_NN '_'' and_CC thus_RB the_DT
        half-life_NN of_IN bone_NN collagen_NN is_VBZ similar_JJ in_IN premenopausal_NN and_CC
        postmenopausal_NN women_NNS ._. In_IN a_DT study_NN comprising_VBG larger_JJR cohorts_NNS ,_,
        a_DT small_JJ but_CC significant_JJ elevation_NN in_IN the_DT α_NN L_NNP /_NN β_NN Lratio_NNP was_VBD
        found_VBN ,_, indicating_VBG that_IN the_DT net_JJ half-life_NN of_IN collagen_NN is_VBZ
        slightly_RB decreased_VBN after_IN the_DT menopause_NN [_NN 16_CD ]_NN ._.
        In_IN breast_NN cancer_NN patients_NNS affected_VBN by_IN bone_NN metastases_NNS
        (_( HC_NNP +_NN patients_NNS and_CC NC_NNP +_NN patients_NNS )_) ,_, the_DT levels_NNS of_IN all_DT CTX_NNP
        isoforms_NNS were_VBD elevated_VBD compared_VBN with_IN healthy_JJ postmenopausal_NN
        controls_NNS or_CC with_IN NC-_NNP patients_NNS ._. The_DT α_NN Lform_NNP representing_VBG the_DT
        degradation_NN of_IN newly_RB formed_VBN bone_NN was_VBD ,_, however_RB ,_, more_JJR
        elevated_VBD than_IN the_DT corresponding_JJ age-related_JJ isoforms_NNS (_( Table_NNP
        1_LS )_) ._. HC_NNP +_NN patients_NNS had_VBD a_DT 3_CD ._. 4_CD -_: fold_VB elevation_NN in_IN α_NN LCTX_NNP levels_NNS ,_,
        and_CC a_DT 2_CD ._. 2_CD -_: fold_VB elevation_NN was_VBD seen_VBN in_IN NC_NNP +_NN patients_NNS ,_,
        indicating_VBG that_IN the_DT more_RBR severe_JJ condition_NN in_IN the_DT HC_NNP +_NN
        patients_NNS is_VBZ reflected_VBN by_IN the_DT α_NN LCTX_NNP marker_NN ._. The_DT least_JJS
        prominent_JJ elevation_NN was_VBD seen_VBN for_IN the_DT α_NN DCTX_NNP levels_NNS ._.
        The_DT α_NN L_NNP /_NN α_NN DCTX_NNP ratio_NN reflecting_VBG the_DT relative_JJ contents_NNS of_IN
        age-modified_JJ CTX_NNP forms_NNS was_VBD highly_RB increased_VBN in_IN HC_NNP +_NN patients_NNS
        (_( 1_CD ._. 5_LS -_: fold_VB and_CC 1_CD ._. 6_CD -_: fold_VB compared_VBN with_IN NC-patients_NNP and_CC with_IN
        postmenopausal_NN patients_NNS ,_, respectively_RB )_) and_CC in_IN NC_NNP +_NN patients_NNS
        (_( 2_CD ._. 2_LS -_: fold_VB and_CC 2_CD ._. 4_CD -_: fold_VB compared_VBN with_IN NC-_NNP patients_NNS and_CC with_IN
        postmenopausal_NN patients_NNS )_) ._. This_DT suggests_VBZ that_IN the_DT age_NN and_CC
        thus_RB the_DT half-life_NN of_IN collagen_NN type_NN I_PRP fragments_VBZ generated_VBN
        by_IN resorption_NN is_VBZ decreased_VBN in_IN the_DT group_NN of_IN patients_NNS with_IN
        bone_NN metastases_NNS ._. Such_JJ a_DT decrease_NN in_IN collagen_NN type_NN I_PRP
        half-life_NN is_VBZ likely_JJ to_TO reflect_VB a_DT significant_JJ imbalance_NN
        between_IN anabolic_JJ and_CC catabolic_JJ processes_NNS at_IN the_DT focal_JJ area_NN
        of_IN metastatic_JJ invasion_NN [_NN 11_CD ]_NN ._.
        A_DT similar_JJ imbalance_NN is_VBZ seen_VBN in_IN some_DT '_POS high-turnover_JJ '_POS
        conditions_NNS ,_, including_VBG Paget_NNP 's_POS disease_NN [_NN 9_CD 17_CD ]_NN ._. In_IN
        situations_NNS of_IN high_JJ bone_NN turnover_NN ,_, the_NNP '_POS aged_VBN '_POS bone_NN matrix_NN
        will_MD rapidly_RB be_VB replaced_VBN with_IN a_DT new_JJ matrix_NN ,_, leading_VBG to_TO a_DT
        lower_JJR residence_NN time_NN (_( i_NNP ._. e_SYM ._. half-life_NN )_) of_IN bone_NN collagen_NN ._.
        More_JJR '_POS young_JJ bone_NN '_'' (_( as_IN reflected_VBN by_IN the_DT α_NN LCTX_NNP levels_NNS )_) will_MD
        be_VB resorbed_JJ and_CC the_DT relative_JJ content_NN of_IN age-modified_JJ forms_NNS
        will_MD decrease_VB ._. The_DT relative_JJ content_NN of_IN α_NN LCTX_NNP is_VBZ reflected_VBN
        in_IN the_DT CTX_NNP ratios_NNS ,_, providing_VBG an_DT index_NN of_IN bone_NN collagen_NN
        half-life_NN [_NN 9_CD ]_NN ._. Among_IN the_DT CTX_NNP ratios_NNS ,_, the_DT α_NN L_NNP /_NN α_NN Dratio_NNP
        showed_VBD the_DT most_RBS pronounced_VBN elevation_NN in_IN the_DT metastatic_JJ
        breast_NN cancer_NN patients_NNS ._. This_DT is_VBZ in_IN good_JJ agreement_NN with_IN
        kinetic_JJ studies_NNS of_IN the_DT isomerisation_NN and_CC racemisation_NN
        reactions_NNS ,_, where_WRB it_PRP was_VBD shown_VBN that_IN the_DT α_NN DCTX_NNP form_NN
        accumulates_NNS with_IN the_DT lowest_JJS kinetic_JJ rate_NN [_NN 9_CD ]_NN ._. The_DT α_NN L_NNP /_NN α_NN
        DCTX_NNP ratio_NN will_MD thus_RB be_VB most_RBS affected_VBN by_IN changes_NNS of_IN bone_NN
        turnover_NN processes_VBZ influencing_VBG the_DT half-life_NN of_IN collagen_NN
        type_NN I_PRP in_IN the_DT bone_NN matrix_NN ._. The_DT age-related_JJ β_NN Lform_NNP
        accumulates_NNS with_IN a_DT slightly_RB higher_JJR kinetic_JJ rate_NN than_IN α_NN DCTX_NNP
        [_NN 9_CD ]_NN ._. This_DT is_VBZ also_RB apparent_JJ from_IN the_DT less_RBR pronounced_JJ
        increase_NN in_IN the_DT α_NN L_NNP /_NN β_NN Lratio_NNP compared_VBD with_IN the_DT α_NN L_NNP /_NN α_NN Dratio_NNP
        in_IN metastatic_JJ patients_NNS ._.
        When_WRB individual_JJ 
        Z_NNP scores_NNS of_IN CTX_NNP were_VBD calculated_VBN for_IN
        the_DT metastatic_JJ breast_NN cancer_NN patients_NNS compared_VBN with_IN the_DT
        non-metastatic_JJ patients_NNS ,_, the_DT α_NN LCTX_NNP form_NN and_CC the_DT α_NN L_NNP /_NN α_NN DCTX_NNP
        ratio_NN showed_VBD the_DT highest_JJS average_NN increases_NNS in_IN accordance_NN
        with_IN the_DT ability_NN of_IN the_DT α_NN LCTX_NNP levels_NNS and_CC the_DT α_NN L_NNP /_NN α_NN DCTX_NNP
        ratio_NN to_TO most_RBS sensitively_RB reflect_VB alterations_NNS in_IN the_DT
        balance_NN between_IN the_DT anabolic_JJ and_CC catabolic_JJ processes_NNS of_IN
        bone_NN turnover_NN (_( Fig_NNP ._. 3_LS )_) ._. α_NN LCTX_NNP levels_NNS alone_RB showed_VBD a_DT
        significant_JJ elevation_NN in_IN 58_CD %_NN of_IN the_DT metastatic_JJ patients_NNS ,_,
        which_WDT probably_RB reflects_VBZ an_DT increased_VBN bone_NN turnover_NN
        (_( increased_VBN resorption_NN +_NN increased_VBD formation_NN )_) as_IN an_DT
        important_JJ feature_NN in_IN the_DT majority_NN of_IN bone_NN metastatic_JJ
        patients_NNS ._. For_IN the_DT β_NN Land_NNP α_NN DCTX_NNP markers_NNS ,_, respectively_RB ,_, 47_CD
        and_CC 48_CD %_NN of_IN the_DT metastatic_JJ patients_NNS had_VBD levels_NNS 2_CD SDs_NNP above_IN
        the_DT reference_NN level_NN of_IN nonmetastasised_JJ controls_NNS (_( Fig_NNP ._.
        3_LS )_) ._.
        The_DT present_JJ data_NN suggest_VBP that_IN the_DT levels_NNS of_IN α_NN LCTX_NNP are_VBP
        most_RBS affected_VBN by_IN the_DT altered_VBN bone_NN turnover_NN associated_VBN with_IN
        metastatic_JJ invasion_NN of_IN bone_NN ._. The_DT fact_NN that_IN only_RB 58_CD %_NN of_IN
        patients_NNS affected_VBN by_IN bone_NN metastases_NNS (_( as_IN determined_VBN by_IN
        radiology_NN )_) have_VBP increased_VBN levels_NNS of_IN α_NN LCTX_NNP indicates_VBZ a_DT
        rather_RB low_JJ sensitivity_NN of_IN bone_NN resorption_NN markers_NNS to_TO
        identify_VB bone_NN metastases_NNS ._. Several_JJ issues_NNS are_VBP relevant_JJ for_IN
        the_DT interpretation_NN of_IN this_DT result_NN ._. It_PRP may_MD be_VB speculated_VBN
        that_IN different_JJ stages_NNS of_IN the_DT bone_NN metastases_NNS process_VBP show_NN
        varying_VBG release_NN of_IN α_NN LCTX_NNP ._. Furthermore_RB ,_, the_DT difference_NN may_MD
        be_VB related_VBN to_TO differences_NNS between_IN sclerotic_JJ and_CC lytic_JJ bone_NN
        metastases_NNS ._. In_IN this_DT context_NN it_PRP is_VBZ noteworthy_JJ that_IN some_DT
        patients_NNS who_WP have_VBP not_RB been_VBN classified_VBN as_IN having_VBG bone_NN
        metastases_NNS by_IN radiological_JJ methods_NNS have_VBP α_NN LCTX_NNP values_NNS
        increased_VBN more_JJR than_IN 2_CD SDs_NNP above_IN the_DT normal_JJ mean_NN ._.
        High_JJ levels_NNS of_IN α_NN LCTX_NNP are_VBP indicative_JJ of_IN an_DT increased_VBN
        bone_NN resorption_NN ._. In_IN the_DT clinical_JJ management_NN of_IN individual_JJ
        patients_NNS affected_VBN with_IN breast_NN cancer_NN ,_, an_DT increased_VBN α_NN LCTX_NNP
        value_NN may_MD indicate_VB the_DT presence_NN of_IN bone_NN metastases_NNS and_CC will_MD
        call_VB for_IN a_DT closer_RBR clinical_JJ evaluation_NN of_IN the_DT patient_NN and_CC /_NN or_CC
        initiation_NN of_IN preventive_JJ therapy_NN (_( e_SYM ._. g_SYM ._.
        bisphosphonates_NNS )_) ._.
        The_DT study_NN has_VBZ some_DT limitations_NNS ._. Most_JJS patients_NNS received_VBD
        antineoplastic_JJ hormonal_NN treatment_NN (_( 20_CD mg_NN tamoxifen_NN ,_, 500_CD mg_NN
        aminoglutethimide_NN ,_, 500_CD mg_NN provera_NN )_) ._. This_DT treatment_NN may_MD
        potentially_RB reduce_VB bone_NN resorption_NN ,_, thereby_RB influencing_VBG CTX_NNP
        levels_NNS ._. It_PRP may_MD thus_RB be_VB a_DT confounding_VBG factor_NN in_IN the_DT
        analysis_NN ._. In_IN spite_NN of_IN this_DT treatment_NN ,_, however_RB ,_, patients_NNS
        affected_VBN by_IN bone_NN metastases_NNS had_VBD highly_RB increased_VBN marker_NN
        values_NNS compared_VBN with_IN healthy_JJ controls_NNS ._. This_DT indicates_VBZ that_IN
        the_DT increase_NN in_IN markers_NNS is_VBZ related_VBN to_TO metastatic_JJ invasion_NN
        of_IN bone_NN and_CC is_VBZ reflected_VBN in_IN systemic_JJ marker_NN levels_NNS
        regardless_RB of_IN the_DT potential_JJ antiresorptive_JJ effects_NNS of_IN
        antineoplastic_JJ therapy_NN ._.
      
      
        Conclusion_NNP
        Assays_NNP for_IN the_DT various_JJ age-related_JJ isoforms_NNS of_IN CTX_NNP have_VBP
        different_JJ sensitivities_NNS to_TO identify_VB patients_NNS affected_VBN by_IN
        bone_NN metastases_NNS ._. The_DT α_NN LCTX_NNP isoform_NN reflecting_VBG resorption_NN
        of_IN young_JJ bone_NN appeared_VBD to_TO provide_VB the_DT best_JJS differentiation_NN
        of_IN patients_NNS affected_VBN by_IN breast_NN cancer-induced_JJ bone_NN
        metastases_NNS ._. Further_RB studies_VBZ are_VBP needed_VBN to_TO investigate_VB the_DT
        utility_NN of_IN this_DT marker_NN in_IN the_DT early_JJ detection_NN of_IN bone_NN
        metastases_NNS and_CC for_IN assessing_VBG treatment_NN efficacy_NN ._. Such_JJ
        studies_NNS should_MD correlate_VBP marker_NN values_NNS with_IN metastasis_NNS type_NN
        (_( lytic_JJ ,_, sclerotic_JJ ,_, mixed_JJ )_) and_CC with_IN the_DT volume_NN of_IN bone_NN
        affected_VBN by_IN metastases_NNS ._.
      
      
        Competing_VBG interests_NNS
        Paul_NNP Cloos_NNP ,_, Stephan_NNP Christgau_NNP and_CC Per_IN Qvist_NNP are_VBP
        employees_NNS of_IN Nordic_NNP Bioscience_NNP A_DT /_NN S_NNP ,_, which_WDT commercializes_NNS
        the_DT CTX_NNP immunoassays_NNS ._. Per_IN Qvist_NNP and_CC Claus_NNP Christiansen_NNP own_JJ
        shares_NNS in_IN Nordic_NNP Bioscience_NNP A_DT /_NN S_NNP ._. Jean-_NNP Jacques_NNP Body_NNP and_CC Nina_NNP
        Lyubimova_NNP have_VBP no_DT competing_VBG interests_NNS ._.
      
      
        Abbreviations_NNP
        α_NN D_NNP =_SYM D-_NNP aspartyl_NN peptide_NN ;_: α_NN L_NNP =_SYM L-_NNP aspartyl_NN peptide_NN ;_: β_NN D_NNP =_SYM
        D-_NNP isoaspartyl_NN peptide_NN ;_: β_NN L_NNP =_SYM L-_NNP isoaspartyl_NN peptide_NN ;_: Cr_NNP =_SYM
        creatinine_NN ;_: CTX_NNP =_SYM crosslinked_JJ C-_NNP telopeptide_NN of_IN type_NN I_PRP
        collagen_NN ;_: ELISA_NNP =_SYM enzyme-linked_JJ immunosorbent_NN assay_NN ,_, HC_NNP +_NN =_SYM
        hypercalcemic_JJ with_IN bone_NN metastases_NNS ;_: NC_NNP +_NN =_SYM normocalcemic_JJ
        with_IN bone_NN metastases_NNS ;_: NC-_NNP =_SYM normocalcemic_JJ without_IN
        radiological_JJ signs_NNS of_IN bone_NN metastases_NNS ;_: SD_NNP =_SYM standard_JJ
        deviation_NN ._.
      
    
  
